Short Term Price Target on Zoetis (ZTS)

Zoetis (NYSE:ZTS) : The most positive equity analysts on Zoetis (NYSE:ZTS) expects the shares to touch $62, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $53.13 with an expected fluctuation of $5.72 from the mean.

Zoetis Inc. has lost 0.71% in the last five trading days and dropped 0.61% in the last 4 weeks. Zoetis Inc. is up 5.93% in the last 3-month period. Year-to-Date the stock performance stands at -0.33%. Also, Jefferies maintains its view on Zoetis (NYSE:ZTS) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $57 per share to $58 per share on Zoetis . The rating by the firm was issued on June 14, 2016.

Zoetis (NYSE:ZTS) : 6 brokerage houses believe that Zoetis (NYSE:ZTS) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Zoetis (NYSE:ZTS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 10 Wall Street Analysts endorse the stock as a Buy with a rating of 1.8.

Zoetis (NYSE:ZTS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $47.19 and $46.97 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $47.53. The buying momentum continued till the end and the stock did not give up its gains. It closed at $47.46, notching a gain of 0.47% for the day. The total traded volume was 3,769,037 . The stock had closed at $47.24 on the previous day.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.